Gemcitabine Hydrochloride Market Report 2026

The gemcitabine hydrochloride market size has grown strongly in recent years. It will grow from $0.83 billion in 2025 to $0.89 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growth in cancer incidence rates, approval of gemcitabine-based regimens, expansion of oncology hospitals, increased chemotherapy utilization, rising investment in cancer research.

The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growth of combination oncology therapies, expansion of cancer care infrastructure, rising prevalence of solid tumors, development of biosimilars, increasing oncology drug access. Major trends in the forecast period include increasing use in combination chemotherapy, rising demand for injectable oncology drugs, expansion of hospital-based cancer treatments, growing focus on precision oncology, increasing adoption in multiple cancer types.

The increasing incidence of breast cancer is expected to drive the growth of the gemcitabine hydrochloride market in the coming years. Breast cancer is a form of cancer that originates in breast cells, most commonly in the milk ducts or glands. Rising life expectancy contributes to the growing number of breast cancer cases, as aging increases the likelihood of genetic mutations accumulating over time, thereby raising disease risk. Gemcitabine hydrochloride is used in breast cancer treatment because it disrupts DNA replication, effectively slowing the rapid proliferation of malignant cells. For instance, in February 2025, according to the International Agency for Research on Cancer, a US-based health organization, breast cancer cases are projected to reach 3.2 million new diagnoses annually by 2050. Therefore, the rising incidence of breast cancer is driving the growth of the gemcitabine hydrochloride market.

Major companies operating in the gemcitabine hydrochloride market are concentrating on advancing novel therapies, such as perioperative immunotherapy, to improve overall treatment effectiveness. Perioperative immunotherapy involves administering cancer treatment both before surgery (neoadjuvant) and after surgery (adjuvant) to enhance clinical outcomes and lower the risk of disease recurrence. For instance, in March 2025, AstraZeneca, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Imfinzi (durvalumab). This approval represents the first and only perioperative immunotherapy authorized for the treatment of muscle-invasive bladder cancer (MIBC). The therapy combines Imfinzi with chemotherapy agents, including gemcitabine and cisplatin, prior to surgery, followed by continued treatment with Imfinzi alone after surgery. Clinical trial results demonstrated improved survival rates and a reduced risk of cancer recurrence.

In December 2024, Cheplapharm, a Germany-based pharmaceutical company, acquired Gemzar from Eli Lilly for an undisclosed sum. This acquisition enhances CHEPLAPHARM’s oncology portfolio by adding the well-established chemotherapy drug Gemzar, which is used in the treatment of several cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based producer of gemcitabine hydrochloride, marketed under the brand name Gemzar.

Major companies operating in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the gemcitabine hydrochloride market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gemcitabine hydrochloride market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gemcitabine hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gemcitabine hydrochloride market by increasing the cost of imported active pharmaceutical ingredients and sterile manufacturing inputs. These impacts have been most visible in injectable oncology drug segments in North America and Europe. Asia-Pacific manufacturers have faced pricing pressures due to api import reliance. However, tariffs have supported domestic api manufacturing and strengthened oncology drug supply resilience.

The gemcitabine hydrochloride market research report is one of a series of new reports that provides gemcitabine hydrochloride market statistics, including gemcitabine hydrochloride industry global market size, regional shares, competitors with a gemcitabine hydrochloride market share, detailed gemcitabine hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. This gemcitabine hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gemcitabine hydrochloride is a synthetic nucleoside analog that disrupts DNA synthesis, thereby inhibiting cell division. It is widely used in research related to cellular replication because of its ability to incorporate into DNA strands and halt replication. Once inside the cell, it is phosphorylated into its active form and integrated into DNA, causing chain termination and initiating programmed cell death.

The main products of gemcitabine hydrochloride include injections, solutions, and other forms. The injectable form is administered directly into the bloodstream using a syringe or intravenous system. It can be delivered via intravenous, subcutaneous, or intramuscular routes and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is used in the treatment of pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and other cancers.

The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.